Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia

Leukemia

Volumn 14, Issue 8, 2000, Pages 1371-1377

  Fenaux, P ^a   Chevret, S ^a   Guerci, A ^a   Fegueux, N ^a   Dombret, H ^a   Thomas, X ^a   Sanz, M ^a   Link, H ^a   Maloisel, F ^a   Gardin, C ^a   Bordessoule, D ^a   Stoppa, A M ^a   Sadoun, A ^a   Muus, P ^a   Wandt, H ^a   Mineur, P ^a   Whittaker, J A ^a   Fey, M ^a   Daniel, M T ^a   Castaigne, S ^a   Degos, L ^a   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid

Indexed keywords

CYTARABINE; DAUNORUBICIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

EID: 0033890197     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401859     Document Type: Article

References (41)

1. Proposals for the classification of the acute leukemias
2. A variant form of hypergranular promyelocytic leukemia (M3)
3. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
4. The PML-RAR alpha fushion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
5. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML
6. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia
7. Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral homorrhage
8. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia?
9. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital
10. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients
11. Treatment of acute promyelocytic leukemia: A report on 70 cases
12. Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG trial)
13. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
14. All-trans retinoic acid in promyelocytic leukemias. II
15. All-trans retinoic acid as a differentiating therapy for acute promyelocytic leukemias. I. Clinical results
16. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid)
17. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients
18. Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid
19. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
20. All-trans retinoic acid in acute promyelocytic leukemia
21. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
22. AIDA protocol (all-trans retinoic acid + idarubicin) in the treatment of newly diagnosed acute promyelocytic leukemia (APL): A pilot study of the Italian cooperative group GIMEMA
23. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia. A pilot study on 26 cases
24. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience
25. Nonparametric estimation from incomplete observations
26. Regression models and life-tables (with discussion)
27. Asymptotically efficient rank invariant test procedures (with discussion)
28. Tretinoin with chemotherapy in newly diagnosed acute promylocytic leukemia
29. Presenting while blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
30. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
31. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PML/RAR isoform, and CD13 expression in patients treated with all-trans retinoic acid
32. Prognostic significance of the RT-PCR assay of PML-RARα transcripts in acute promyelocytic leukemia
33. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for PML-RAR fusion mRNA
34. Reverse transcription polymerase chain reaction for PML-RAR fusion transcripts in acute promyelocytic leukemia and its application to minimal residual detection
35. Monitoring of treatment outcome in acute promylelocytic leukemia by RT-PCR
36. Continuous treatment with all-trans RA progressively decreases plasma drug concenrations: Implications for relapse and resistance in acute promyelocytic leukemia
37. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
38. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
39. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
40. A modified AIDA protocol with anthracyclin based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML-RAR α-positive acute promyelocytic leukemia
41. Therapy of molecular relapse in acute promyelocytic leukemia